Home Administrative Billing & Reimbursement BlueCard® Health and Wellness Medical PEAR portal Pharmacy Products Quality Management

Updates to the list of specialty drugs that will require precertification

December 2, 2019

Effective January 1, 2020, the following specialty drugs, which are eligible for coverage under the medical benefit for Independence commercial and Medicare Advantage HMO and PPO members, will require precertification:

  • Eylea® (aflibercept) – Ophthalmic agents
  • KanjintiTM (trastuzumab-anns) – Cancer
  • Lucentis® (ranibizumab) – Ophthalmic agents
  • Macugen (pegaptanib) – Ophthalmic agents
  • PolivyTM (polatuzumab vedotin-piiq) – Cancer
  • Revatio® (sildenafil) – Pulmonary arterial hypertension
  • RuxienceTM (rituximab-pvvr) – Cancer
  • SynojoyntTM (sodium hyaluronate) – Hyaluronate acid products
  • TriluronTM (sodium hyaluronate) – Hyaluronate acid products
  • Tyvaso® (treprostinil) – Pulmonary arterial hypertension
  • Ventavis® (iloprost) – Pulmonary arterial hypertension
  • Zirabev (bevacizumab-bvzr) – Cancer

In addition, the following drugs are currently pending approval from the U.S. Food and Drug Administration (FDA) and will require precertification for Independence members once they receive FDA approval in 2020, or as of January 1, 2020, for any drug approved in 2019:

  • abicipar – Ophthalmic agents
  • brolucizumab – Ophthalmic agents
  • casimersen – Duchenne muscular dystrophy
  • cosyntropin depot – Endocrine/metabolic agents
  • crizanlizumab – Miscellaneous therapeutic agents
  • eptinezumab – Miscellaneous therapeutic agents
  • givosiran – Miscellaneous therapeutic agents
  • golodirsen – Duchenne muscular dystrophy
  • isatuximab – Cancer
  • Lapelga (pegfilgrastim) – Colony-stimulating factor
  • lisocabtagene maraleucel – Chimeric antigen receptor therapy
  • margetuximab – Cancer
  • Reblozyl (luspatercept-ammt) – Miscellaneous therapeutic agents
  • RVT-802 – Miscellaneous therapeutic agents
  • viltolarsen – Duchenne muscular dystrophy
  • Zynteglo (betibeglogene darolentivec) – Gene Therapy

Lastly, the following drugs will no longer require precertification approval from Independence as of January 1, 2020:

  • Beleodaq® (belinostat) – Cancer
  • FolotynTM (pralatrexate) – Cancer
  • Imlygic® (talimogene laherparepvec) – Cancer
  • Istodax® (romidepsin) – Cancer
  • Monovisc® (high molecular weight hyaluronan) – Hyaluronate acid products

Learn more

In the absence of a published medical policy on any of these newly approved drugs, all requests will be subject to review in accordance with the FDA-approved indications and Independence-recognized compendia.

These changes are reflected in an updated precertification requirement list, which has been posted to our website.


This content was prepared for the Provider News Center and may not be reproduced in any way without the express written permission of Independence Blue Cross. Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association.
Connect with us     Facebook     Twitter     Flickr     YouTube     Walk the Talk    Independence Pinterest    Independence LinkedIn    Independence Instagram Site Map        Anti-Fraud        Privacy Policy        Legal        Disclaimer
© 2023 Independence Blue Cross.
Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association, serving the health insurance needs of Philadelphia and southeastern Pennsylvania.